SEKISUI CHEMICAL CO., LTD.



For FY2024, ended March 31, 2025

Presentation of Financial Results and the FY2025 Management Plan

Keita Kato

President and CEO

April 28, 2025

Main Points of Today's Presentation



					★ : Record high
(JPY billion)	FY2024 Results	Compared with FY2023	Difference from Forecasts (January 2025)	FY2025 Plan	Compared with FY2024
Net sales	★ 1,297.8	+41.2	-9.9	★ 1,364.5	+66.7
Operating profit	★ 108.0	+13.6	+1.0	★ 115.0	+7.0
Ordinary profit	★ 111.0	+5.0	+5.0	★ 116.6	+5.6
Profit attributable to owners of parent	★ 81.9	+4.0	+1.9	★ 82.0	+0.1
Dividend per share (JPY)	★ 79	+5	+2	★ 80	+1
ROE (%)	10.2	-0.2	+0.2	10.0	-0.2
	continued weak global marke				-


FY2024 Results	Despite continued weak global market conditions, secured increases in net sales and operating profit on the back of high- performance product sales growth and thoroughgoing efforts to secure margins; operating profit exceeded forecasts (January 2025), surpassing ¥100 billion; record highs at each level of profit ROE of 10.2%.
FY2025 Plan	Plan to increase net sales and operating profit; operating profit projected to total ¥115 billion in line with the Medium-term Plan by continuing to expand sales of high-performance products and maintaining margins; target record highs at each level of profit; Despite an uncertain outlook surrounding tariffs and foreign currency exchange rates, minimize the effects through various means, including passing on to selling prices and optimizing manufacturing and sales allocation; Plan for ROE of 10.0%
Returns to Shareholders	FY2024: Increase in dividends of ¥2 per share compared with forecasts (January 2025); period-end dividend of ¥42 per share for an annual dividend of ¥79 per share (up ¥5 per share YoY) and a fifteenth consecutive FY of dividend growth; undertook the repurchase and cancellation of 4 million treasury shares (repurchase amount of ¥8.9 billion) FY 2025: Plan to pay an annual dividend of ¥80 per share, up ¥1 per share for a sixteenth consecutive FY of dividend growth; establish a limit for the acquisition of treasury shares (maximum: 4 million shares / ¥10.8 billion); plan to cancel treasury shares (4 million shares)

1. Investment Plan and Progress

- Increase in growth investment projects; strategic capital investments projected to exceed budgeted limits set under the Medium-term Plan
- Ongoing efforts to search for M&A and other projects focusing on growth areas Operating cash flows

(JPY billion)

(JPY billion)	FY23-25 Plan	FY23-24 Results	
Strategic investments	Limit 450.0	100.4	
M&A, etc.	Limit 300.0	1.2	
Capital expenditures	150.0	99.2	
ESG investment (included within strategic and normal investments)	30.0	29.0	
Normal investments	150.0	95.4	
Total	600.0	195.8	
R&D expenditure	140.0	85.9	



2. Strategic Innovation - Accelerated Growth -

- Strengthening efforts to launch new businesses
- Steady progress in the perovskite solar cell business

Growth potential businesses	Key themes and progress
Perovskite solar cells	 Decision made to engage in mass production to a scale of 100MW Ongoing efforts to engage in demonstration activities through external collaboration
Biorefinery	 Demonstration phase posing challenges for stable production
Overseas development of infrastructure materials	 Strengthening overseas marketing Steady FFU growth in Europe; pipeline renewal growth

3. Strengthen the ESG Management Platform

Steady progress in key KPIs for sustainable growth

Key issues	Review of FY2023
Products to enhance sustainability	FY24 sales (preliminary data): ¥996.6 yen (+¥46.4 billion YoY) Group-wide sales ratio growth: FY23: 76% \rightarrow FY24: 77%
GHG emission reduction rate	FY24 forecasts -41%(BM: FY19) Medium-term Plan: -33% Reduction rate maintained at the level reached under the Medium-term Plan through growth in the switch to renewable energy overseas
Human capital	FY24 wage increase rate: More than 5% Employee challenge action rate: FY23: 48% \rightarrow FY24: 56%

Returns to Shareholders

Continue to actively provide returns to shareholders in FY2025 in line with the mediumterm policy; work toward a sixteenth consecutive FY of dividend growth

Returns to Shareholders Track Record (JPY billion)		Previous Medium-term Management Plan	Medium-term Management Plan
Acquisition of treasury shares Total dividend payment	Dividend payout ratio	35% or higher	40% or higher
Net profit attributable to owners of parent	DOE	3% or higher	3% or higher
56.7 60.9 63.5 66.1 58.9 69.3 77.9 81.9 82.0 41.5 37.1 27.4 16.2 8.9 10.8	Total return ratio	50% or higher if the D/E ratio is less than 0.5	50% or higher if the D/E ratio is less than 0.5 Implement additional returns as appropriate, taking into account the investment progress under the Medium- term Management Plan, cash position, and stock price
16.8 16.4 16.0 14.6 13.3 12.2 9.5 14.7 16.8 19.0 20.5 21.1 21.2 21.9 25.6 31.4 33.1 33.2	Cancellation of treasury shares	Cancel newly acquired shares to the extent that total treasury shares do	Cancel newly acquired shares to the extent that total treasury shares do not
FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 Plan		not exceed 5% of outstanding shares	exceed 5% of outstanding shares

Fiscal year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025 Plan
Net profit attributable to owners of parent per share (JPY)	115.1	126.1	133.8	141.7	128.8	91.9	83.2	159.2	183.5	196.0	197.0
Cash dividend per share (JPY)	30	35	40	44	46	47	49	59	74	79	80
Payout ratio	26.1%	27.7%	29.9%	31.0%	35.7%	51.1%	58.9%	37.0	40.3	40.4	40.4
Acquisition of treasury shares (JPY billion)	16.8	16.4	16.0	14.6	13.3	12.2	9.5	27.4	16.2	8.9	10.8
Total return ratio*1	55.5%	54.5%	55.1%	53.0%	58.3%	80.4%	84.6%	76.5%	61.0%	51.2%	52.6%
DOE*2	2.8%	3.1%	3.3%	3.4%	3.5%	3.3%	3.3%	3.7%	4.2%	4.1%	4.0%
Cancellation of treasury shares (thousands of shares)	10,000	-	10,000	8,000	8,000	8,000	5,000	15,000	8,000	4,000	4,000

*1 Total return ratio = (Amount of treasury shares acquired + Total dividends) / Net profit attributable to owners of parent Copyright@ SEKISUI CHEMICAL CO., LTD.

*2 DOE = Total dividend payment (full year) / Average equity

FY2024 Results

	FY2	023	FY2024				
Forex rate	1H	2H	1H	2H			
In-house assumptions	-	-	-	¥153/US\$ ¥162/€			
Results (Avg. rate for each term)	¥141/US\$ ¥153/€	¥148/US\$ ¥160/€	¥153/US\$ ¥166/€	¥153/US\$ ¥162/€			

* Export data is subject to in-house assumptions regarding foreign currency exchange rates. A ¥1 depreciation in the value of the yen against the USD has the effect of increasing operating profit by approximately ¥500 million each year at the assumed in-house rate.

Ikusuke Shimizu

Representative Director Senior Managing Executive Officer Head of Business Strategy Department

Overview of FY2024 Results



★ : Record high

- Increase in net sales; third consecutive FY of record-high sales
- Increase and record high at each level of profit (operating profit, ordinary profit, and profit attributable to owners of parent); achieved operating profit in excess of ¥100 billion
- Each level of profit (operating profit, ordinary profit, and profit attributable to owners of parent) exceeded forecasts (January 2025)
- Dividend up ¥2 per share compared with forecasts (January 2025); annual dividend per share of ¥79, up ¥5 (period-end dividend of ¥42 per share)

(JP	Y billion)	FY2023	FY2024	Difference	FY2024 Forecasts (Jan.)	Difference
	Net sales	1,256.5	★ 1,297.8	+41.2	1,307.7	-9.9
	Operating profit	94.4	★ 108.0	+13.6	107.0	+1.0
	Ordinary profit	105.9	★110.0	+5.0	106.0	+5.0
	Profit attributable to owners of parent	77.9	★ 81.9	+4.0	80.0	+1.9
	Dividend per share (JPY)	74	★ 79	+5	77	+2

FY2024 Results by Segment

- Increase in net sales across three segments, excluding the Housing Company; increase in operating profit across all segments; operating profit in excess of forecasts (January 2025) on a Group-wide basis
 - HPP*: Growth driven by high-performance products in the Electronics field; increase in net sales and substantial increase in operating profit
 - Housing*: Despite a downturn in the number of houses sold owing to the delayed recovery in new housing market conditions (in regional areas), substantial increase in operating profit due to the effects of measures aimed at strengthening profitability and an increase in orders in the Renovation Business
 - UIEP*: Despite weak conditions in the housing market in Japan and slump in non-residential market conditions, increase in net sales and operating profit owing to improvement in selling prices and growth in prioritized product sale
 - Medical: Record high net sales and operating profit owing to the growth in sales of infectious disease testing kits in the U.S. as well as mainstay pharmaceutical ingredients and the impact of foreign currency exchange rates

FY2023		FY2024		Difference		FY2024 Forecasts (Jan.)			Difference		
(JPY billion)	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit		let Iles	Operating profit	Net sales	Operating profit
HPP	412.9	50.9	★ 447.4	★ 61.2	+34.5	+10.3	4	51.1	61.0	-3.7	+0.2
Housing	529.7	27.7	524.0	31.5	-5.7	+3.8	5	23.7	31.1	+0.3	+0.4
UIEP	234.8	22.1	★ 240.5	★ 23.0	+5.7	+0.8	2	44.0	24.4	-3.5	-1.4
Medical	92.6	11.0	★ 99.2	★ 12.8	+6.6	+1.8	1	01.5	12.6	-2.3	+0.2
Other	7.3	-10.8	7.6	-11.6	+0.3	-0.8		8.5	-12.1	-0.9	+0.5
Eliminations or corporate expenses	-20.7	-6.5	-20.8	-8.9	-0.1	-2.4	-2	21.1	-10.0	+0.3	+1.1
Total	1,256.5	94.4	★ 1,297.8	★ 108.0	+41.2	+13.6	1,3	07.7	107.0	-9.9	+1.0

• Other: PV* down ¥1.0 billion, LB* down ¥1.3 billion, BR* down ¥2.2 billion, R&D and other down ¥7.1 billion

* HPP: High Performance Plastics Company, Housing: Housing Company, UIEP: Urban Infrastructure & Environmental Products Company

* PV:Perovskite Solar Cell Business, LB: Stationary Lithium-Ion Batteries Business, BR: Biorefinery Business


1H & 2H FY2024 Results by Segment

- Achieved an increase in operating profit across all segments in both the 1H and 2H
- Substantial increase in operating profit in the HPP and Housing companies as well as the Medical Business in the 2H; continued steady increase in operating profit in the UIEP Company

	1H F)	(2023	1H FY	2024	Difference		Difference		nce 2H FY2023		2H FY2024		Difference	
(JPY billion)	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operatin g profit	Net sales	Operating profit	Net sales	Operatin g profit		
HPP	200.3	23.0	★ 221.1	★ 29.9	20.8	+6.9	212.6	28.0	★ 226.2	★ 31.4	+13.6	+3.4		
Housing	264.8	13.0	253.7	14.6	-11.2	+1.6	264.9	14.8	270.4	16.9	+5.5	+2.2		
UIEP	109.7	8.1	★ 113.4	★ 8.5	3.8	+0.4	125.1	14.1	127.1	★ 14.5	+1.9	+0.4		
Medical	43.7	5.1	★ 47.9	★ 6.0	4.2	+0.8	48.9	5.8	★ 51.3	6.8	+2.4	+1.0		
Other	3.2	-5.1	3.5	-5.9	0.3	-0.8	4.1	-5.7	4.1	-5.7	0	0		
Eliminations or corporate expenses	-10.3	-2.9	-10.5	-4.2	-0.2	-1.4	-10.4	-3.7	-10.3	-4.7	+0.1	-1.1		
Total	611.3	41.2	★ 629.1	★ 48.7	17.8	+7.6	645.2	53.2	★ 668.7	★ 59.2	+23.5	+6.0		

FY2024 Results Analysis

Despite weak market conditions both in Japan and overseas, substantial increase in sales volumes and product mix owing to high-performance product sales growth; high raw material prices and increase in fixed costs, including investments in human capital offset by improvements in selling prices; buoyed also by the impact of foreign exchange gains, increase in net sales and operating profit; operating profit in excess of forecasts (January 2025)



FY2025 Plan

	FY2	024	FY2	025
Forex rate	1H	2H	1H	2H
In-house assumptions	-	-	¥152/US\$ ¥159/€	¥152/US\$ ¥159/€
Results (Avg. rate for each term)	¥153/US\$ ¥166/€	¥153/US\$ ¥162/€	-	-

* Export data is subject to in-house assumptions regarding foreign currency exchange rates. A ¥1 depreciation in the value of the yen against the USD has the effect of increasing operating profit by approximately ¥500 million each year at the assumed in-house rate.

FY2025 Plan: Overview and Returns to Shareholders



- Planning an increase in net sales, to achieve the operating profit target set under the Medium-term Plan, and increases at each level of profit (operating profit, ordinary profit, and profit attributable to owners of parent)
- Planning for record-high net sales for a third consecutive FY; targeting record highs at each level of profit
- Planning to pay a dividend per share of ¥80, up ¥1 per share (working toward a sixteenth consecutive FY of dividend growth)
- Establish a limit for the acquisition of treasury shares (maximum: 4 million shares / ¥10.8 billion); planning to cancel treasury shares (4 million shares)


(JPY billion)	FY2024	FY2025 Plan	Difference
Net sales	1,297.8	★ 1,364.5	+66.7
Operating profit	108.0	★ 115.0	+7.0
Ordinary profit	111.0	★ 116.6	+5.6
Profit attributable to owners of parent	81.9	★ 82.0	+0.1
Dividend per share (JPY)	79	* 80	+1

Outlook for Market Conditions




Number of Automobiles Manufactured (YoY)

4Q FY2024: Results slightly above expectations FY2025: Forecasts at roughly the same level as the previous year



Smartphone Shipments (YoY)

4Q FY2024: Results in line with forecasts at the same level as the previous year FY2025: Forecasts slightly above the previous year



Housing • Visitors (YoY)

2H FY2024: Despite an increase in requests for materials via such media as the WEB, overall results below the previous year FY2025: Trends to remain unchanged

	1H FY24	2H FY24	1H FY25	2H FY25
Overall visitors	105%	97% [103%]	97%	98%
Via WEB	119%	103% [110%]	98%	96%
Exhibition visitors	91%	86% [93%]	91%	100%


New Housing Starts

* Figures in parentheses are Forecasts (Jan.)

Continued gradual decline in construction starts


* Timing when demand for each of the UIEP Company's products can be expected to emerge: From four to six months after the start of residential construction

* Figures in parentheses are forecasts (Jan.)



Domestic Naphtha Price Assumptions

4Q FY2024: Results slightly above forecasts FY2025: Forecasts slightly below FY2024 levels



FY2025 Plan by Segment

- Increases in net sales and operating profit in each segment; plans for record-high operating profit in three segments, excluding the Housing Company
- Continue to create new businesses and strengthen the internal control system
 - HPP: Planning an increase in net sales and record-high operating profit by continuing to focus on expanding sales of high-performance products
 - Housing: While new housing orders are forecast to come in at roughly the same level as the previous year, planning an increase in net sales and operating profit on the back of higher unit prices and Renovation Business growth
 - UIEP: Planning an increase in net sales and record-high operating profit on the back of prioritized product sales growth, an increase in overseas sales, and thoroughgoing efforts to secure margins
 - Medical: Targeting record high net sales and operating profit by capturing diagnostics demand in Japan and overseas and strengthening new orders in the Pharmaceutical Sciences Business

• Other: PV down ¥4.0 billion, LB down ¥0.8 billion	, BR down ¥2.8 billion, R&D and other down ¥6.3 billion
---	---

	FY2024			2025 an	Difference		
(JPY billion)	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	
HPP	447.4	61.2	★ 482.9	★ 64.0	+35.5	+2.8	
Housing	524.0	31.5	★ 540.0	36.0	+16.0	+4.5	
UIEP	240.5	23.0	★ 251.8	★ 26.0	+11.3	+3.0	
Medical	99.2	12.8	★ 102.2	★ 14.5	+3.0	+1.7	
Other	7.6	-11.6	9.0	-13.8	+1.4	-2.2	
Eliminations or corporate expenses	-20.8	-8.9	-21.4	-11.8	-0.6	-2.8	
Total	1,297.8	108.0	★ 1,364.5	★ 115.0	+66.7	+7.0	

Copyright© SEKISUI CHEMICAL CO., LTD.

1H & 2H FY2025 Plans by Segment


- Planning an increase in net sales and operating profit in the HPP and Housing companies in the 1H; targeting record-high net sales and operating profit across three segments, excluding the Housing Company
- Planning an increase in net sales and operating profit on a Group-wide basis and across all segments in the 2H; planning for record-high net sales and record-high operating profit across three segments, excluding the Housing Company

	1H F)	/2024	1H FY	2025	Differ	ence	2H F)	/2024	2H FY	2H FY2025		rence
(JPY billion)	Net sales	Operatin g profit	Net sales	Operating profit	Net sales	Operatin g profit	Net sales	Operatin g profit	Net sales	Operating profit	Net sales	Operatin g profit
HPP	221.1	29.9	★ 238.5	★30.9	+17.4	+1.0	226.2	31.4	★ 244.4	★33.1	+18.2	+1.7
Housing	253.7	14.6	262.0	16.0	+8.3	+1.4	270.4	16.9	★ 278.0	20.0	+7.6	+3.1
UIEP	113.4	8.5	★ 114.5	★ 8.5	+1.1	0	127.1	14.5	★ 137.3	★17.5	+10.2	+3.0
Medical	47.9	6.0	★ 49.3	★ 6.0	+1.4	0	51.3	6.8	★ 52.9	★ 8.5	+1.6	+1.7
Other	3.5	-5.9	4.6	-6.4	+1.1	-0.5	4.1	-5.7	4.4	-7.4	+0.3	-1.7
Eliminations or corporate expenses	-10.5	-4.2	-10.9	-6.1	-0.4	-1.9	-10.3	-4.7	-10.5	-5.6	-0.2	-0.9
Total	629.1	48.7	★ 658.0	★ 48.9	+28.9	+0.2	668.7	59.2	★ 706.5	★ 66.1	+37.8	+6.9

FY2025 Plan Analysis



- Forecasting an increase in sales volumes and product mix on the back of continued efforts to focus on high-performance product sales growth
- Planning an increase in operating profit by offsetting the increase in fixed costs associated with human capital investments and the launch of new businesses with an increase in sales volumes and product mix, improvements in selling prices, and cost reduction, etc.




Drive 2.0 Progress: Numerical Targets


12.9


12.0




	FY2022 Results	FY2025 Plan	Medium-term Plan (FY2025 Targets)	Difference			
Net sales	¥1,242.5 bn.	¥1,364.5 bn.	¥1,410.0 bn.	-¥45.5 bn.			
Operating profit (OPM)	¥91.7 bn. (7.4%)	¥115.0 bn. (8.4%)	¥115.0 bn. (8.2%)	¥0.0 (+0.2%)			
Net profit	¥69.3 bn.	¥82.0 bn.	¥82.0 bn.	¥0.0 bn.			
ROIC	7.6%	8.6%	8.5%	+0.1%			
ROE	10.0%	10.0%	11.0%	-1.0%			
Overseas sales (ratio)	¥375.1 bn. (30%)	¥456.7 bn. (33%)	¥480.0 bn. (34%)	-¥23.3 bn. (-1%)			
EBITDA	¥142.1 bn.	¥176.0 bn.	¥175.0 bn.	+¥1.0 bn			
By segment HPP — Housing — UIEP — Medical —							









diagnostics and

reach forecasts

Pharmaceutical Sciences

(overseas) results failed to

businesses, diagnostics

Contributions from highperformance product sales growth mainly in the Electronics and Mobility fields driving substantial Group-wide growth

Prolonged impact from the downturn in housing market conditions; despite the effects of measures aimed at strengthening Medium-term Plan by expanding profitability, progress under the Medium-term Plan one year behind schedule


Despite continued weak market conditions in Japan, plan to exceed targets set under the sales of prioritized products and securing margins

Copyright© SEKISUI CHEMICAL CO., LTD.

Drive 2.0 Progress: Difference from the Medium-term Plan




- Despite net sales failing to reach targets set under the Medium-term Plan, achieve operating profit target by strengthening profitability (= earning power)
- Offset sales volumes and product mix falling below forecasts due to changes in market conditions through improvements in selling prices and successful efforts to control fixed costs; contributions also from foreign exchange gains



Drive 2.0 Progress: Consolidated Performance



Despite various changes and a downturn in market conditions, continued steady growth to the point of achieving targets set under the Medium-term Plan



ROIC by Segment

After PF reorganization

(%)	FY2023	FY2024
Medical	9.2	9.6
HPP	12.7	12.8
Housing	12.7	13.6
UIEP	9.7	10.5

* Medical Business included in the HPP Company prior to FY2017

* Data from FY2022 after portfolio reorganization

Copyright© SEKISUI CHEMICAL CO., LTD.

(Reference) Impact of U.S. Tariff Measures and Fluctuations in Foreign Currency Exchange Rates



Despite an uncertain outlook, working to strengthen initiatives aimed at minimizing impacts through self-supporting endeavors

Assumptions and Approach

- Impact of U.S. tariff measures on plans: FY2025 plans were formulated prior to the announcement of tariff measures; accordingly, a specific amount of impact has not been factored into plans
- Actual direct impact of tariff measures: Estimated unplanned risks are presented in the table on the right
- Impact attributable to fluctuations in foreign currency exchange rates:

In-house assumptions regarding FY2025 foreign currency exchange rates:

¥152/US\$, ¥159/€

A ¥1 depreciation in the value of the yen against the USD has the effect of increasing operating profit by approximately ¥500 million each year at the assumed in-house rate.

Estimation of Risks and Countermeasures

Direct Impact of Reciprocal Tariff Measures

Main Details / Assumptions	Estimated Amount of Impact on Operating Profit
 Tariffs on products exported to the U.S. from each location Tariffs on raw materials, etc. imported by U.S. locations from other regions, etc. 	Roughly - ¥2.5 billion
 Countermeasures Pass through to selling prices Optimize manufacturing and sales allocation by increasing production capacity in the U.S. through small investments, etc. 	+ ¥2.5 billion

Other Potential Impacts

	Main Details / Assumptions
Direct impact of tariff measures	 Decrease in U.S. auto imports Retaliatory tariff measures in the EU and other countries, etc.
Impact of fluctuations in foreign currency exchange rates	1Q assumptions: ¥152/US\$ Revised as appropriate according to prevailing rates from the 2Q
Countermeasures	 Increase marginal profit by increasing new sales and expanding sales of high-performance products Continue working to secure additional cost reductions while also controlling fixed costs Increase net sales by expanding businesses in Japan



Tatsuya Nishida

Managing Executive Officer

Head of Corporate Finance & Accounting Department

Number of Consolidated Companies

	Mar. 31, 2024	Mar. 31, 2025	Difference
Consolidated subsidiaries	143	145	Increased: 4 Subsidiaries ^{*1} Decreased: 2 Subsidiaries ^{*2}
Affiliates (Equity Method)	6	6	Increased: 0 Subsidiaries Decreased: 0 Subsidiary

*1 Kofu Sekisui Sangyo Co., Ltd., Toseki Kako Co., Ltd., Shiseki Kako Co., Ltd., Sekisui Solar Film Co., Ltd.

*2 PT. Sekisui Indonesia, Sekisui Chemical India Private Ltd.

Impact of Change in the Number of Consolidated Companies

(JPY billion)	FY2024 (YoY)	Difference
Net sales	-0.4	Sanin Sekisui Shoji Co., Ltd. ^{*3} Kofu Sekisui Sangyo Co., Ltd. ^{*4} Toseki Kako Co., Ltd. ^{*4}
Operating profit	-0.1	Shiseki Kako Co., Ltd. *4 Sekisui Solar Film Co., Ltd. *5

*3 Excluded from the scope of consolidation from the 2Q of FY2023

*4 Newly consolidated from the 1Q of FY2024

*5 Newly consolidated from the 4Q of FY2024

(JPY billion)		F	Y2023	F	Y2024	Di	fference		
Net sales			1,256.5	256.5 1,297.8		+41.2			
Gross profit			392.2		420.6		+28.4		Foreign exchange gains: +7.0
Gross profit marg	gin		31.2%		32.4%		+1.2%		Sekisui Kasei Co., Ltd.: -1.8
Selling, general a expenses	and administrative		297.8		312.7		+14.9		Foreign exchange losses : -0.4
Operating profit			94.4		108.0		+13.6		
Share of profit of for using equity r	entities accounted nethod		0.8		-1.1		-1.9		
Other non-opera expenses	ting profit and		10.7		4.1	•	-6.6		Gain on sale of investment
Ordinary profit		_	105.9		110.0		+5.0		securities: +14.2
Extraordinary pro	ofit		14.2		14.6	•	+0.3		Gain on sale of investment securities: +14.6
Extraordinary los	ses		8.7		5.6	•	-3.1		
Profit before incor	ne taxes		111.5		120.0		+8.5		SDA* fixed asset
Income taxes, et	С.		32.4		35.9		+3.4		Impairment loss + 2.0
Profit attributable interests	to non-controlling		1.1		2.2		+1.1		
Profit attributable to owners of parent			77.9		81.9		+4.0		Sekisui LB Tech Co., Ltd. Impairment loss + 3.7
									Volocopter GmbH
Foreign	1 USD		145 JPY		153 JPY				Loss on stock impairment + 2.0
exchange (Avg. rate)	1 EUR		157 JPY		164 JPY		*SDA : America		ISUI DIAGNOSTICS LLC(North




				Inventories (B/S item)	Mar.31 2025	Difference		
				Ready-built housing (products)	33.3	-4.7		
	Mar. 31, 2024	Mar. 31, 2025	Difference	Prepared land for subdivision housing	69.2	+1.5		
(JPY billion)				Land under preparation (work in process)	9.7	-0.7		
Cash and deposits	138.6	142.6	+4.0	Housing under construction (work in process)	41.1	+10.3		
Trada reasivables	010 5	007 5	F 0	Components, other (raw materials)	5.9	-0.4		
Trade receivables	213.5	207.5	-5.9	Housing Total	159.2	+6.0		
Inventories	298.2	313.8	+15.6	Non-residential total (products, other)	154.6	+9.6		
				Inventories Total	313.8	+15.6		
Other current assets	35.3	39.2	+3.9					
Property, plant and		(00.0		Purchase: +61.7				
equipment	392.5	403.9	+11.4	Depreciation: -42.4				
	50.4	50.4		Foreign exchange: -2.7				
Intangible assets	59.1	59.1	0					
Investment securities	127.4	105.1	-22.3	Sale / redemption: -17.8				
	127.4	105.1	-22.0	Market value: -3.9				
Investments and other assets	58.7	59.6	+0.9					
Total assets	1,323.2	1,330.8	+7.5	Foreign exchange: -9.2				
	1,020.2	1,000.0	+7.5	Consolidated-basis change: +7.5				
				Actual basis: +16.7				


Balance Sheets (Liabilities & Net Assets)



			5.4	
(JPY billion)	Mar. 31, 2024	Mar. 31, 2025	Difference	
Non-interest-bearing liabilities	381.6	384.6	+3.0	
Interest-bearing liabilities	120.7	110.8	-9.9	Net profit: +81.9
[Net interest-bearing liabilities]	[-17.8]	[-31.8]	[-13.9]	Dividends paid: -32.0
Total liabilities	502.3	495.4	-6.9	Cancellation of treasury shares: -7.2
Share capital etc.	208.6	205.1	-3.6	
Retained earnings	501.9	544.8	+42.9	
Treasury shares	-48.7	-50.1	-1.4	Cancellation of
Valuation difference on available-for- sale securities	51.2	36.9	-14.3	treasury shares: +7.2 Purchases of
Non-controlling interests	28.6	28.0	-0.6	treasury shares: -8.9
Other net assets	79.2	70.7	-8.6	
Total net assets	820.9	835.4	+14.4	Foreign currency translation
Total liabilities and net assets	1,323.2	1,330.8	+7.5	adjustment: -5.7
ROIC	7.3%	8.1%	+0.8%	
ROE	10.4%	10.2%	-0.2%	
Equity-to-asset ratio (%)	59.9%	60.7%	+0.8%	
D/E ratio (Net)	-0.02	-0.04	-0.02	

(JPY billion)	FY2023	FY2024
Cash flows from operating activities	106.6	119.2
Cash flows from investing activities	-18.5	-61.5
Cash flows from financing activities	-53.0	-61.2
Net increase in cash and cash equivalents	41.2	-5.5
Cash and cash equivalents at end of period	126.4	120.9
Free cash flow =Cash flows from operating activities + Cash flows from investing activities - Dividends paid	59.0	24.8







	Depreciation*1		Goodwill and other amortization ^{*2}		Capital expenditures		EBITDA*3					
(JPY billion)	FY2023	FY2024	Differ- ence	FY2023	FY2024	Differ- ence	FY2023	FY2024	Differ- ence	FY2023	FY2024	Differ- ence
HPP	21.5	22.3	+0.8	1.2	1.2	0	19.3	26.8	+7.5	73.7	84.8	+11.1
Housing	11.6	11.4	-0.2	0.4	0.4	0	10.2	12.7	+2.6	39.7	43.3	+3.6
UIEP	8.4	8.9	+0.5	0.5	0.3	-0.2	10.8	9.3	-1.6	31.0	32.1	+1.2
Medical	5.3	5.9	+0.6	0.6	0.7	+0.1	6.4	6.1	-0.3	16.9	19.4	+2.5
Other	2.1	1.4	-0.6	0	0	0	2.7	9.3	+6.6	-8.7	-10.2	-1.4
Eliminations or Corporate expenses	1.1	1.2	+0.1	0	0	0	11.3	6.1	-5.1	-5.4	-7.7	-2.3
Total	50.0	51.1	+1.2	2.7	2.6	-0.1	60.6	70.3	+9.7	147.1	★ 161.7	+14.6

*1 Depreciation does not include amortization of M&A intangible assets

*2 Goodwill and other amortization = Goodwill amortization + Amortization of M&A intangible assets


*3 EBITDA = Operating profit + Depreciation + Goodwill and other amortization

Depreciation, Amortization, Capital Expenditures, Research and Development Expenditure

(JPY billion)	FY2024	FY2025 Plan	Difference
Depreciation	51.1	58.8	+7.7
Goodwill and other amortization	2.6	2.2	-0.4
Capital expenditures	70.3	105.0	+34.7
EBITDA	161.7	★ 176.0	+14.3
Research and development expenditure	44.2	47.0	+2.8

Depreciation, Amortization, Capital Expenditures, Research and Development Expenditure

(JPY billion)



High Performance Plastics Company


Akira Asano

Company President


Performance Trends

FY2024: High-performance products in the Electronics fields driving growth; increase in net sales, substantial increase in operating profit

FY2025: Despite the uncertainty surrounding global market conditions, planning an increase in net sales and record-high operating profit focusing mainly on continued growth in sales of high-performance products




Despite sluggish global market conditions, including the automotive sector, increase in net sales and substantial increase in operating profit owing to growth in sales in the Electronics field, focusing mainly on advanced semiconductors, and high-performance interlayer films in the Mobility field; record-high operating profit in the 2H and full FY on the back of a substantial increase in sales volumes and product mix as well as contributions from foreign exchange gains




Overview of FY2025 Plan



Substantial increase in sales volumes and product mix focusing mainly on the Mobility field; plans for an increase in net sales and operating profit by offsetting the effects of higher fixed costs attributable to such factors as the accelerated pace of development over the medium-term and human capital investments through a combination of improvements in selling prices and cost reduction, etc.; target record-high operating profit for a third consecutive FY







designed film, excluding sound insulation film from conventional high-performance interlayer films

Copyright© SEKISUI CHEMICAL CO., LTD.

31




Masahide Yoshida

Company President

Performance Trends


- Housing Company
- FY2024: Despite disparities in the degree of new housing market recovery between regions and a decrease in the number of houses sold owing to delays in the recovery in regional areas, substantial increase in operating profit due to the effects of measures aimed at strengthening profitability in the Housing Business and an increase in orders in the Renovation Business; operating profit exceeded forecasts (January 2025)
- FY2025: Despite little or no likelihood of a recovery in new housing market conditions and expectations that the number of new housing orders will remain roughly the same as the previous year, plan for an increase in net sales and operating profit on the back of a continued increase in unit prices and Renovation Business growth



Copyright© SEKISUI CHEMICAL CO., LTD.

FY2024 Results Analysis


- Substantial increase in operating profit in the Housing Business by offsetting the impact of a decline in the number of houses sold through product mix, cost reduction, etc., and measures aimed at strengthening profitability geared toward reducing fixed costs; growth in Renovation Business orders owing to ongoing efforts to upgrade and expand periodic diagnosis as well as strengthen proposals
- Operating profit across the Housing Company as a whole in excess of forecasts (January 2025)



Overview of FY2025 Plan



- Planning an increase in both net sales and operating profit owing to higher unit prices on the back of improvements in the product mix in the Housing Business and efforts to strengthen sales capabilities in the Renovation Business
- Focus on securing projects aimed at sustainable town and community development growth in the Residential Business






Housing Business

New Housing Orders (YoY)

- FY2024: While urban area orders exhibited a recovery trend, new housing orders were essentially unchanged from the previous year owing to the weak recovery in regional areas
- FY2025: Target an increase in the amount of orders by expanding orders for high-priced products, including detached house rebuilding and apartment buildings




		unt of Or dings by					of	(Yo	Y)	
-	Jane	unge by	1990 01	0011	FY2			FY	25	
				11	ł	2H		1H	2H	
	ing	Rebuildi ng	Number	102	2%	100%	6	98%	101%	
	d housing	New construc tion	Number	86	%	89%	,	93%	97%	
	Detached		Amount	107	7%	102%	6	99%	102%	
	Dei		Number	100%		98%	,	97%	100%	
	Ap	partment	Amount	108	3%	115%	6	105%	103%	
	b	uildings	Number	100)%	105%	6	100%	101%	
		ance of c end of th			FY2	4 1H	F١	(24 2H	FY25 1H	-
		Balance o ders as of			1:	53.5		160.0	160.0	

* Housing only, excluding renovation (Billions of yen)

+33.0


+18.0



Renovation Business

Renovation Orders

- Steady growth through ongoing efforts to upgrade and expand periodic diagnosis as well as capture thermal insulation renovation demand
- Focus on enhancing sales capabilities by strengthening personnel development systems



Real Estate Business Sales


YoY

change

end of the

period*

- Stable growth by increasing the number of dwelling units under management
- Focus also on the purchase and resale as well as asset utilization businesses




Residential Business

+6.5

Town and Community Development Business Sales

Marginal profit

- · Steady growth due to an increase in projects for sale
- Focus on securing projects in the leadup to the next Medium-term Plan



Fixed costs

Urban Infrastructure & Environmental Products Company


Yoshiyuki Hirai

Company President

Performance Trends




- FY2024: Despite weak housing market conditions and sluggish non-residential market conditions in Japan, secured an increase in net sales and operating profit owing to improvements in selling prices and prioritized product sales growth; third consecutive FY of record-high operating profit
- FY2025: Plans for an increase in net sales and operating profit owing to continued prioritized product sales growth, an upswing in overseas sales, and thoroughgoing efforts to secure margins; target record-high operating profit for a fourth consecutive FY and an operating profit margin of at least 10%



Copyright© SEKISUI CHEMICAL CO., LTD.




- Secured an increase in net sales and operating profit on the back of improvements in selling prices and prioritized product sales growth; third consecutive FY of record-high operating profit
- Delays in construction and a deterioration in the movement of cargo in the 4Q owing to overtime restrictions in the construction industry; despite efforts to contain fixed costs, results fell below forecasts (January 2025)



UIEP Company

Overview of FY2025 Plan

- Domestic housing and non-residential market conditions expected to trend along the same lines as the previous year; capital investment demand projected to follow a recovery trend toward the 2H
- Planning an increase in net sales and operating profit on the back of efforts to offset the upswing in total costs through prioritized product sales growth, an increase in overseas sales, and steps to entrench new prices
 - Japan: Focus on expanding prioritized product sales centered on earthquake-resistant polyethylene pipes, fire-resistant products, and water storage panel tanks
 - Overseas: Focus on expanding new CPVC product sales; focus on capturing new FFU and pipeline renewal orders






Net sales in the Three Strategic Fields and KPI's

Pipe Systems



- While housing and non-residential market conditions trend along the same lines as the previous year, recovery in capital investment demand in the 2H; expand sales of prioritized products and work thoroughly to secure margins
- CPVC: Work to expand market share through new competitively priced products




· Pipeline renewal

Japan: Acquire properties within the FY based on the results of nationwide surveys

- Overseas: Acquire new orders through collaboration with construction partners
- Aqua System

Focus on large-scale plant equipment and facilities as well as water storage panel tank orders




Copyright© SEKISUI CHEMICAL CO., LTD.

Building and Infrastructures Composite Materials

Fire resistant a flammable ma

Performance materials (railroad sleepers, etc.)

- · Fire-resistant and non-flammable materials: Target growth by cultivating new customers
- FFU (railway sleeper application): Aim to expand adoption mainly in Europe
- · Prefabricated baths: Focus on capturing nursing care (wells) and renovation demand



Prioritized Products Sales Overseas Sales* by Region Growth Driving Business Sales (Japan) Focus on expanding new CPVC product sales in Asia Pipeline renewal Expecting growth mainly in earthquake-resistant Fire-resistant and Expecting growth mainly in North America (pipeline non-flammable materials polyethylene pipes and fireresistant products renewal) and Europe (FFU) Construction and industrial piping Asia, other Performance materials Prioritized product sales/domestic sales Europe (JPY billion) (railroad sleepers, etc.) North America 28% 29% 25.0 25% 24% (YoY) 20.2 20.1 2.6 195 (115%)(104%) (100%) (102%) 1.6 1.32.1 (JPY billion) 3.4 3.6 37 32.1 27. 26.6 8.2 226 15.4 15. 13.7 2H 1H 2H 1H 2H 1H 2H 1H 1H 2H 1H 2H FY24 FY24 FY25 FY25 FY24 FY24 FY25 FY25 FY24 FY24 FY25 FY25

* Including the export of domestic products




Eiichi Takahashi

President of SEKISUI MEDICAL CO., LTD

Performance Trends




- FY2024: Record-high net sales and operating profit on the back of increased sales of infectious disease testing kits in the U.S. and mainstay pharmaceutical ingredients as well as the effects of foreign exchange
- FY2025: Work to capture diagnostics demand in Japan and overseas and strengthen efforts to capture new orders in the Pharmaceutical Science Business while targeting record-high net sales and operating profit for second consecutive FY



FY2024 Results Analysis


- Despite falling below forecasts, substantial growth in infectious disease testing kits in the U.S. and contributions from firm mainstay pharmaceutical ingredients helped drive an increase in net sales and operating profit
- Results generally in line with forecasts (January 2025) on the back of successful efforts to control fixed costs



Overview of FY2025 Plan



- Despite the anticipated impact of such factors as a certain decrease in product shipments to major customers in the U.S., planning an increase in operating profit by steadily capturing demand for diagnostics reagents in Japan and new orders in the Pharmaceutical Science Business
- Achieve annual net sales in excess of ¥100 billion and operating profit of ¥14.5 billion; aim for record-high net sales and operating profit






Net sales by Business and Overview of Progress

Diagnostics (Japan)


- FY2024: Steadily captured immunology testing demand
- FY 2025: Continued immunology testing sales growth and target new orders through efforts to bring new coagulation devices to market



Pharmaceutical Sciences (Pharmaceutical and Fine Chemicals, Drug Development Solutions, Enzymes)

Pharmaceutical science (CDMO)


- FY2024: Firm orders of mainstay pharmaceutical ingredients and drug development solutions
- FY2025: Focus on capturing new orders



Diagnostics (overseas)


Overseas testing system

- FY2024: Despite a drop in testing demand in China, secured an increase in net sales owing to infectious disease testing kit sales growth in the U.S.
- FY2025: Work to capture new customers by introducing new coagulation devices in China; anticipating the impact of such factors as a certain decrease in product shipments to major customers in the U.S.



Trends in Net Sales of Priority Infectious Disease Testing Kits

- FY2025 FLU/COVID-19 demand is expected to remain normal
- Continue to steadily capture demand



This slide presentation contains forward-looking statements. These statements are based on current expectations and beliefs. However, actual results may differ from those expressed or implied due to a number of factors and uncertainties such as changes in the global economy and our business, competition in the market, and regulatory issues.

Note: Figures denominated in units of 100 million JPY are rounded off to the nearest hundred million.

Housing Company Results and Plan



1.	Main data in Housing business		FY2024	FY2023			
		1H	2H	Full Year	1H	2H	Full Year
	Net sales (JPY billion)	253.7	270.4	524.0	264.8	264.9	529.7
0	Housing	165.2	172.2	337.3	175.3	172.6	348.0
Ň	Renovation	53.8	53.4	107.2	50.9	52.4	103.3
CONSOLIDATED	Other	34.7	44.7	79.4	38.6	39.9	78.4
_ID/	Real estate	27.6	29.3	56.8	27.3	29.2	56.5
TE	Residential Services	3.4	3.7	7.1	3.6	3.7	7.3
U	Town and Community Development	3.0	11.1	14.1	6.1	5.9	12.0
	Overseas	0.7	0.7	1.4	0.6	0.8	1.4
	1.Number of houses sold (Housing units)	4,315	4,315	8,630	4,675	4,485	9,160
	Detached houses	4,045	3,910	7,955	4,400	4,070	8,470
	Housing/Rebuilding	3,465	3,405	6,870	3,745	3,480	7,225
	Ready-built houses	580	505	1,085	655	590	1,245
	Apartment buildings, other	270	405	675	275	415	690
P	2. Main data						
OTHERS	Prices per unit (JPY million) in the detached houses	36.4	37.7	37.0	34.8	35.7	35.2
	Prices per tsubo** (JPY thousand) in the detached houses **Tsubo=3.3 Square meter	1,077	1,110	1,092	1,010	1,039	1,023
	Floor space (Square meter) in the detached houses	111.6	112.1	111.9	113.7	113.3	113.5
	ZEH ratio	-	-	95%	-	-	96%
	Exhibition places (Units)	400	-	388	430	-	404
С	Sales staff (Number of person)	2,355	-	2,188	2,451	-	2,241



Group-wide		FY2	024			FY2	023		FY2022				
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
HPP	110.6	110.5	112.0	114.2	96.1	104.2	106.0	106.6	99.1	102.4	97.9	97.0	
Housing	116.2	137.4	132.0	138.4	121.0	143.8	126.7	138.1	115.7	144.5	129.0	148.2	
UIEP	52.5	60.9	60.8	66.2	51.3	58.4	59.8	65.3	50.1	60.3	59.2	64.7	
Medical	22.3	25.5	25.1	26.2	20.5	23.2	23.7	25.3	20.6	22.3	22.4	24.4	

HPP		FY2	023		FY2022							
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Electronics	15.7	16.9	17.8	15.6	12.6	14.8	14.2	13.7	15.7	12.9	13.1	11.6
Mobility	58.7	58.6	58.0	61.2	48.9	55.0	57.4	57.8	43.2	49.3	48.6	50.2
Industrial	26.6	26.5	26.8	26.9	24.3	24.9	24.1	25.4	26.7	27.1	25.2	25.4

Electronics field		FY2	023		FY2022							
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Liquid Crystal	4.8	5.1	5.3	5.1	4.7	4.9	4.8	4.5	5.8	3.7	4.1	4.2
Non-LCD	10.9	11.7	12.5	10.5	7.9	9.8	9.5	9.3	9.9	9.2	9.0	7.3
Non-LCD field sales ratio	70%	69%	70%	67%	62%	68%	66%	67%	63%	71%	69%	63%

Mobility field		FY2	:024			FY2	:023		FY2022				
	1Q	2Q	3Q	4Q	1Q 2Q 3Q 4Q			4Q	1Q	2Q	3Q	4Q	
YoY high performance interlayer film sales volume	112%	100%	95%	108%	98%	102%	107%	103%	98%	119%	102%	98%	

Various Performance Data

SEKISUI

Industrial field		FY2	024			FY2	023		FY2022				
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
Labor-saving product	5.9	6.0	5.8	7.0	4.9	5.2	4.8	5.6	6.0	5.6	4.8	5.3	
Environmentally friendly product	1.9	1.9	2.2	2.2	1.7	2.1	2.0	2.2	1.9	1.9	2.1	2.1	
Housing		FY2	024			FY2	023			FY2	022		
■Net Sales (JPY billion)	11	4	21	H	11	H	21	4	11	H	21	ł	
Housing		7.9		9.0		6.7		7.9		9.5		11.2	
Renovation		5.0		4.9		4.0		4.2		3.6		4.3	
Other		1.6		3.1		2.2		2.6		1.7		2.7	
UIEP		FY2	024			FY2023				FY2	022		
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
Pipe Systems	26.8	31.0	30.1	30.2	25.3	29.6	30.1	29.1	25.7	29.8	29.5	28.6	
Building and Infrastructures Composite Materials	18.2	20.6	21.3	19.9	18.4	20.0	20.5	19.7	17.3	20.8	20.9	20.4	
Infrastructure Renovation	5.9	7.4	7.1	13.5	5.5	7.0	7.2	14.1	5.0	6.9	5.9	12.7	
UIEP		FY2	024			FY2	023			FY2	2022		
■Net Sales (JPY billion)	11	4	21	1	11	1	21	4	11	H	21	4	
Prioritized Products(Japan)		22.6		27.1		19.5		26.5		19.0		24.3	

Overseas		20.2		20.1		19.5		19.9		22.2		19.5
Medical Business		FY2	024			FY2	023		FY2022			
Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Diagnostics (Japan)	7.6	8.4	8.7	7.9	7.6	8.0	8.7	8.0	7.8	7.3	8.1	7.7
Diagnostics (overseas)	11.2	11.8	11.9	12.7	9.4	10.0	11.2	12.0	8.9	10.4	10.6	11.2
Pharmaceutical Sciences	3.5	5.4	4.4	5.6	3.6	5.2	3.8	5.3	3.9	4.5	3.7	5.5
Igino del los diferitorite dos, eres						1	1	·····i	· · · · · · · · · · · · · · · · · · ·		····· ł	

SEKISUI